의료용 아이소토프 시장 : 유형별, 용도별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Medical Isotope Market By Type (Stable Isotopes, Radioisotopes), By Application (Diagonestic, Nuclear Therapy), By End User (Hospitals, Diagnostic Centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,925,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,278,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 의료용 아이소토프 시장은 2023-2032년의 CAGR 8.8%로, 2022년 51억 4,250만 달러에서 성장하며, 2032년에는 113억 9,790만 달러에 달할 것으로 예측되고 있습니다.

의료용 동위원소는 의료 전문가들이 심장병, 암과 같은 건강 상태를 진단하고 치료하기 위해 사용합니다. 의료용 동위원소 생산은 원자로와 입자 가속기(선형 가속기, 사이클로트론)라는 두 가지 종합적인 기술을 사용하여 이루어집니다.

핵의학은 갑상선 질환, 폐 질환, 골질환, 신경 질환 등 다양한 질병에 대한 방사선 치료를 개선하기 위해 활용되고 있습니다. 핵의학(방사성동위원소) 산업은 연구, 진단 및 치료를 위한 방사성 물질의 사용, SPECT 및 PET의 사용 증가, 핵의학에 대한 헬스케어 교육 및 인식 제고가 특징입니다. 암, 심혈관 질환, 신경 질환과 같은 질병의 유병률이 증가함에 따라 핵의학 영상진단과 같은 정밀 진단 툴에 대한 수요가 증가하고 있습니다. 새로운 방사성의약품과 영상진단 장비가 개발됨에 따라 핵의학 치료는 더욱 효과적이고 안전해지고 있습니다. 이러한 발전은 핵의학의 용도를 넓히고 그 사용을 증가시키고 있습니다. 이러한 요인들은 향후 수년간 의료용 동위원소 시장의 성장을 가속할 것으로 예상됩니다.

동위원소란 양성자 수는 같고 중성자 수가 변하는 화학 원소를 말합니다. 의료, 산업, 과학 연구 등 다양한 분야에서 활용되고 있습니다. 그러나 동위원소의 제조 및 구매 비용이 비싸기 때문에 폭넓은 활용이 제한되어 있습니다. 동위원소 제조에는 원자로나 입자 가속기와 같은 전문 장비가 필요한 경우가 많습니다. 이러한 장비는 건설 및 운영 비용이 많이 듭니다. 동위원소 취급 및 제조에는 엄격한 안전 규정이 필요하며, 이는 인프라 및 운영 비용을 증가시킵니다. 이러한 요인들은 예측 기간 중 의료용 동위원소 시장의 성장을 제한할 것으로 예상됩니다.

양전자방출단층촬영(PET) 및 단일광자방출컴퓨터단층촬영(SPECT)과 같은 진단 영상 기술의 지속적인 발전은 의료용 동위원소를 사용하여 정확하고 비침습적인 의료 영상 촬영에 사용할 수 있는 기회를 창출합니다. 이러한 이미징 기술이 계속 발전함에 따라 적절한 동위원소에 대한 수요는 증가할 것으로 예상됩니다. 의료용 동위원소의 치료 용도, 특히 암 치료(방사성의약품 치료)는 큰 성장 기회를 가지고 있습니다. 알파선 방출 핵종 및 베타선 방출 핵종과 같은 표적 핵종 치료의 연구개발은 암 치료에 사용되는 동위원소의 유형를 확대하는 데 기여하고 있습니다. 또한 핵의학 방사성동위원소에 대한 수요는 새로운 SPECT 및 PET 용도의 개발과 함께 증가하고 있습니다. 또한 2021년 12월에 개최된 RSNA21에서 GE헬스케어는 가장 고성능의 핵의학 장비인 SPECT/CT를 발표했습니다. 이러한 발전은 의료 및 핵의학 기술에서 방사성동위원소 개발을 가속화할 것으로 예상됩니다. 이러한 모든 요인들이 향후 수년간 의료용 동위원소 시장의 성장을 가속할 것으로 예상됩니다.

COVID-19는 초기에 핵의학과 같은 비(非)코로나 진단과 치료를 일시적으로 중단하거나 연기함으로써 핵의학 방사성동위원소 산업에 부정적인 영향을 미쳤습니다. 예를 들어 2021년 6월 ScienceDirect Journal에 게재된 보고서에 따르면 COVID-19 확진자 및 사망자 수가 증가하는 동안 핵의학 검사, 심장 핵의학 영상 및 암 PET/CT의 수는 전염병 기간 중 감소했다고 합니다. 이 연구에 따르면 2020년 6월부터 2021년 2월까지 COVID-19 확진자 감소로 인해 수술이 증가한 것으로 나타났습니다. 그러나 2022년 초부터 COVID-19 확진자 수가 감소함에 따라 방사선 시술 측면에서 시장은 대유행 이전 수준에 근접하고 있으며, 이는 핵의학 방사성동위원소에 대한 수요 증가로 이어지고 있습니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 의료용 동위원소 시장 분석 시장 부문, 현재 동향, 추정 및 동향, 역학을 정량적으로 분석하여 의료용 동위원소 시장의 유력한 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter의 다섯 가지 힘 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 공급업체의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 의료용 동위원소 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 의료용 동위원소 시장 동향, 주요 기업, 시장 부문, 용도, 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서에서 가능한 커스터마이징

• 제품수명주기
• 기술 동향 분석
• 국가, 지역 및 세계 수준의 환자/역학 데이터
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 예측
• 크리스 크로스 부문 분석 - 시장 규모 및 예측
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)
• 고객/소비자/원료 공급업체 리스트 - 밸류체인 분석
• 세계/지역/국가별 기업의 시장 점유율 분석
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 시장 점유율 분석
• 밸류체인 분석
• 규제 가이드라인
• 특허 상황

제4장 의료용 아이소토프 시장 : 유형별

• 개요
• 안정동위체
• 방사성동위원소

제5장 의료용 아이소토프 시장 : 용도별

• 개요
• 진단
• 핵의학 요법

제6장 의료용 아이소토프 시장 : 최종사용자별

• 개요
• 병원
• 진단 센터
• 연구기관

제7장 의료용 아이소토프 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 러시아
  • 이탈리아
  • 기타
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • UAE
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Canadian Nuclear Laboratories(CNL)
• Curium
• GE Healthcare
• Jubilant Radiopharma
• Nordion Inc.
• IBA Radiopharma Solutions
• Mallinckrodt Pharmaceuticals
• northstar medical radioisotopes, llc
• Eczacibasi-Monrol Nuclear Products
• Isotopen Technologien Munchen(ITM)

KSA

영문 목차

영문목차

The global medical isotopes market is anticipated to reach $11,397.9 million by 2032, growing from $5,142.5 million in 2022 at a CAGR of 8.8% from 2023 to 2032.

Medical isotopes are used by medical professionals to diagnose and treat health conditions such as heart disease and cancer. The production of medical isotopes is achieved by using two overarching technologies: nuclear reactors and particle accelerators (linear accelerators, cyclotrons).

Nuclear medicine is being utilized to improve radiotherapy for a variety of ailments, including thyroid problems, lung diseases, bone diseases, and neurological disorders. The nuclear medicine (radio isotopes) industry is characterized by the use of radioactive materials for research, diagnosis, and therapy, as well as the rising use of SPECT and PET, as well as healthcare education and awareness about nuclear medicine. The increasing prevalence of diseases such as cancer, cardiovascular disease, and neurological issues has led to an increase in the demand for precise diagnostic tools such as nuclear medicine imaging. Nuclear medicine treatments have become more effective and safer as new radiopharmaceuticals and imaging instruments are being developed. These developments have broadened the applications of nuclear medicine and increased its use. These factors are expected to boost the growth of the medical isotopes market in the upcoming years.

Isotopes are chemical elemental varieties with the same number of protons but a variable number of neutrons. They are used in a variety of fields, including medicine, industry, and scientific study. However, the manufacturing and purchase of isotopes can be expensive, limiting their broad use. Isotope production frequently necessitates the use of specialist equipment such as nuclear reactors or particle accelerators. These facilities can be costly to construct and operate. Handling and manufacturing isotopes necessitate tight safety rules, which raises the cost of infrastructure and operations. These factors are expected to limit the growth of the medical isotopes market during the forecast period.

Ongoing advancements in diagnostic imaging technologies, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), create opportunities for the use of medical isotopes in accurate and non-invasive medical imaging. As these imaging techniques continue to evolve, the demand for suitable isotopes is likely to increase. The therapeutic applications of medical isotopes, particularly in cancer treatment (radiopharmaceutical therapy), offer substantial growth opportunities. R&D in targeted radionuclide therapies, such as alpha and beta emitters, contribute to expanding the range of isotopes used for cancer treatment. In addition, the demand for nuclear medicine radioisotopes is increasing as new SPECT and PET applications are developed. In addition, at RSNA21 in December 2021, GE Healthcare announced its most sophisticated SPECT/CT, a nuclear medicine system. These advances are expected to accelerate the development of radioisotopes in medicine and nuclear medicine techniques. All these factors are anticipated to drive the medical isotopes market expansion in the upcoming years.

The COVID-19 pandemic initially had a negative influence on the nuclear medicine radioisotopes industry by temporarily canceling or postponing non-COVID diagnosis and treatment, such as nuclear medicine. For example, according to a report published in ScienceDirect Journal in June 2021, the number of nuclear studies, nuclear cardiac imaging, and cancer PET/CT reduced throughout the pandemic while COVID-19 cases and deaths increased. According to the study, operations increased from June 2020 to February 2021 as COVID-19 instances decreased. However, with the drop of COVID-19 cases since early 2022, the market in terms of radiological procedures is approaching pre-pandemic levels, which is leading to an increase in demand for nuclear medicine radioisotopes.

The key players profiled in this report include Canadian Nuclear Laboratories (CNL), Curium, GE Healthcare, Jubilant Radiopharma, Nordion (Canada) Inc, IBA Radiopharma Solutions, Mallinckrodt Pharmaceuticals, NorthStar Medical Radioisotopes, Eczacibasi-Monrol Nuclear Products, and Isotopen Technologies Munchen (ITM). The market players are continuously striving to achieve a dominant position in this competitive market using strategies such as collaborations and acquisitions.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the medical isotope market analysis from 2022 to 2032 to identify the prevailing medical isotope market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the medical isotope market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global medical isotope market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Product Life Cycles
• Technology Trend Analysis
• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• List of customers/consumers/raw material suppliers- value chain analysis
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Application

• Diagonestic
• Nuclear Therapy

By Type

• Stable Isotopes
• Radioisotopes

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Canadian Nuclear Laboratories (CNL)
• Curium
• GE Healthcare
• Jubilant Radiopharma
• Nordion Inc.
• IBA Radiopharma Solutions
• Mallinckrodt Pharmaceuticals
• northstar medical radioisotopes, llc
• Eczacibasi-Monrol Nuclear Products
• Isotopen Technologien Munchen (ITM)

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. Market Share Analysis
• 3.6. Value Chain Analysis
• 3.7. Regulatory Guidelines
• 3.8. Patent Landscape

CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Stable Isotopes
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Radioisotopes
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Diagonestic
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Nuclear Therapy
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Diagnostic Centers
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Research Institutes
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. UK
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. France
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Russia
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Italy
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. South Korea
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. Australia
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Type
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. UAE
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. South Africa
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by End User
    • 7.5.5.5. Rest of LAMEA
    • 7.5.5.5.1. Market size and forecast, by Type
    • 7.5.5.5.2. Market size and forecast, by Application
    • 7.5.5.5.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Canadian Nuclear Laboratories (CNL)
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Curium
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. GE Healthcare
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Jubilant Radiopharma
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Nordion Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. IBA Radiopharma Solutions
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Mallinckrodt Pharmaceuticals
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. northstar medical radioisotopes, llc
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Eczacibasi-Monrol Nuclear Products
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Isotopen Technologien Munchen (ITM)
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료